A Systematic Review of the Association between the Age of Onset of Spinal-Bulbar Muscular Atrophy (Kennedy’s Disease) and the Length of CAG Repeats in the Androgen Receptor Gene

Background

Spinal-bulbar muscular atrophy (SBMA), or Kennedy’s disease, is an X-linked recessive motor neuron disorder associated with greater than 38 CAG repeats in the androgen receptor gene (1), that affects approximately 1/40,000 men (although prevalence is greater in certain locations, such as the Vaasa region of Finland) (2). Increased CAG expansion induces toxic polyQ-AR fragments, resulting in the disruption of transcription, mitochondrial function, protein cycling, cell signaling pathways and autophagy (1,3). The average age of onset of SBMA is in the third or fourth decade and, although female carriers display some symptoms of the condition such as distal motor deficits, cramping and/or fasciculations (1), men are much more severely impacted (4) with symptoms that include dysarthria, dysphagia, gynecomastia, cramping, fasciculations and tremor (1).

Generally, SBMA follows a gradual progression with postural tremors of the upper limbs starting in the early thirties (5). In addition to the onset of dysarthria and dysphagia in the forties, lower limb motor deficits also develop, eventually requiring the use of walking aids in the fifth decade (5). Finally, patients become wheelchair-bound by, or during, their sixth decade (5). Patients with bulbar musculature implicated early-stage SBMA often die from recurrent aspiration pneumonia in their fifties (6).

Although it is known that the age of onset of non-motor manifestations of SBMA is independent of CAG repeat length, primary literature does indicate that there is also a clear negative correlation between the age of onset of motor manifestations and CAG repeat number (for review see (4)). Although several studies (5–17) have pondered the relationship between CAG repeat number and the age of the most frequent symptom of SBMA, weakness (18), to date, no systematic review has specifically focused on the possible connection between these two factors. As such, herein we seek to address this deficit by exploring the effect of a greater number of CAG repeats on the age of weakness onset in comparison to a lower number of CAG repeats in male SBMA patients (between the ages of 11 and 83) who did not suffer from other major chronic illnesses.

Given that very little is known about the aetiology of SBMA, probably due to its relatively low prevalence in the population, and that current treatments for SBMA only facilitate symptom management, men with the condition should be identified as soon as possible in order for treatment to begin promptly (4). As such, any addition to the SBMA-associated literature which increases understanding of the disease must be welcomed.

Objectives

Primary literature was reviewed in order to:

1. Explore whether or not the association between CAG repeat number and age of onset of symptoms of SBMA was, or was not, significant.

2. Determine what minimum and maximum number of CAG repeats was associated with weakness onset in SBMA.

Materials and Methods

Study Identification

Searches were conducted between September and October 2021, by an independent reviewer, and after searching ‘Spinal Bulbar Muscular Atrophy’ and ‘CAG repeat’ on EBSCO, the most commonly cited database was PubMed (a.k.a. MEDLINE). PubMed was searched using the following combined terms that were designed to address three concepts: “spinal bulbar muscular atrophy”, “age of onset of muscle weakness”, and “CAG repeat”, which yielded 116 results. Additional searches were made of the SCOPUS and Web of Science databases, utilizing variations of the same three concepts, which generated 390, and three results, respectively. Individual searches were also conducted in two journals: firstly, Cambridge University Press where the abbreviated term “SBMA” was used (yielding two results), and the Annals of Neurology: Wiley Online Library where the search terms for a specific author of interest (“Manabu Doyu”) were used, in addition to the disease of interest (“spinal bulbar muscular atrophy”). This search yielded six results (see Appendix A, S1 for list of search terms and also Fig. 1 for the process utilized for our searches).

• Download figure
• Open in new tab

Fig 1. Flow chart of screening, and criteria for inclusion and exclusion of articles (8)

Results

Our literature search yielded 13 papers eligible for inclusion in this review. The study design of these 13 articles was as follows: ten quantitative observational (7,9–17), one quantitative longitudinal prospective (18), and two quantitative longitudinal retrospective studies (5,19). There were four Japanese studies (5,7,9,12), one German (11), one Canadian (18), one Polish (13), one Taiwanese (19), one Italian (10), two Korean (14,17), one Chinese (16), and one American study (15). Table 4 summarizes the main results of each study. Populations varied depending on the country in which each study took place. Sample sizes ranged between 14 to 223 patients.

Objective 1: To explore whether or not the association between CAG repeat number and age of onset of symptoms of SBMA was, or was not, significant

All thirteen eligible studies did examine the relationship between CAG repeat expansion and the age of onset of weakness in SBMA patients (5,7,9–19). These studies could be broadly divided into two groups based on how the authors assessed weakness: studies that used a scoring system to assess weakness and other signs, and studies that used informal patient interviews and/or chart reviews only. Two studies used a combination of methods from both groups (5,14). In the first group, scoring systems included the activity of daily living scores (to assess the onset and severity of weakness) (9,10,14,17), the Limb Norris score, Norris Bulbar score and ALS functional rating scale-revised to assess symptoms and signs of SBMA (12), the Neuropathy Impairment Score to assess motor function and symptoms such as weakness (18), an unspecified standard scoring system to assess symptomatology in patients (11) and a scale to grade weakness (7). The second group of studies simply used either patient interviews (7) or both chart reviews and interviews (13–15,19) or just chart reviews (16) to screen symptoms and/or signs of SBMA.

Studies can be separated into three groups regarding the relationship between CAG repeat length and the age of onset of weakness in SBMA patients (see Table 3). The first group includes articles that found a statistically insignificant inverse correlation (19) and a significant correlation (no r value was provided) (7), or no correlation (13). The second group of studies includes those that revealed either a significant moderate inverse relationship between CAG repeats and the age of onset of weakness (5,9,10,14,16–18) or a strong inverse correlation (11,15). Note that the moderate group also contains results obtained from Lee et al. (2005) as, although they claimed a “weak” correlation (r= -0.4) (14), the correlation they identified is actually classified as moderate based on their own published r value (e.g., ± 0.1 to ± 0.3 is weak, ± 0.4 to ± 0.6 is moderate, ± 0.7 to ± 0.9 is strong, and ± 1 is perfect) (21). The strength of each group of correlations is based upon accepted r value classification (21). The third group included a study that compared the number of CAG repeats with weakness onset, and related that to either motor-dominant or sensory-dominant phenotypes of weakness. Fewer CAG repeats were correlated with an older age at onset of weakness in SBMA patients and an older age at examination (p<0.0001) (12).

Objective 2: To determine what minimum and maximum number of CAG repeats are associated with weakness onset in SBMA

As shown in Table 4, although all eligible studies did report the number of CAG repeats, the studies could be subdivided into three groups based on the information provided by each article as follows: 1. A group of five studies that listed the ages of participants alongside the minimum and maximum number of recorded CAG repeat number in a retrievable form (7,9,10,14,18); 2. Seven studies that listed CAG repeat number and age ranges (5,11,13,15–17,19); and, 3. One study that involved a unique experimental design, that did not fit into either of the two previous subgroups (12).

In the first group, the article by Sinnreich et al. (2004) reported the shortest number of CAG repeats at 36 (weakness onset at age 46) ranging up to 55 (weakness onset at 38), with the cut-off for consideration being any patient with a CAG repeat number greater than 35 (18). Mariotti et al. (2000) also reported a minimum CAG repeat number in the thirties, ranging from 39-50, with the patient with the fewest repeats experiencing weakness at age 50 and the two patients with the most repeats experiencing weakness at ages 35 and 31 respectively (10). This study claimed that a normal CAG repeat range was between 12 and 30, and that in SBMA it could be from 39 to 62 (10). There were three studies that reported a minimum number of CAG repeats ≥ 40. Firstly, Doyu et al. (1992) who reported a range of 40-55, noting that the patient with the lowest number of repeats had an age of weakness onset of 70, compared to the patient with the most repeats who experienced weakness onset at age 25 (9). Secondly, Shimada et al. (1995) who identified a slightly greater minimum repeat number of 41 in a patient who experienced a later age-at-weakness-onset (age 49) than another patient who had the greatest CAG repeat number (52, with the onset of weakness at age 44) (7). Finally, Lee et al. (2005) reported the largest minimum CAG repeat number of 45 (age of weakness onset at 55) and a maximum repeat of 54 (onset at 39) (12).

In the second group of studies, the articles by Song et al. (2015) and Rosenbohm et al. (2018) both reported the lowest minimum CAG repeat number of the group at 39 repeats (11,17). However, their reported age ranges and average CAG repeat number differed, in that Song et al. (2015) reported a mean of 44 CAG repeats (range of 39 - 55) and an average age-at-onset of symptoms of SBMA was 44.5 (20.0□71.0) (17), with Rosenbohm et al. (2018) reporting a mean age-at-weakness-onset range of 25–75 years (44.4 ± 12.0) and a mean length of CAG expansion of 46.2 ± 3.3 (range 39.0–55.0) (11).

Three of the seven studies in this group reported a minimum number of CAG repeats of exactly 40. Specifically, Sperfeld et al. (2002) proposed that the threshold for the number of CAG repeats to be considered as normal is 38, and reported a range of 40-42 CAG repeats among their study population (15). Tomik et al. (2006) identified a CAG repeat number range of 45-52, claiming that the number of CAG repeats they considered to be normal was between 5 and 33, but that for SBMA it was between 40 and 62 CAG repeats (13). Atsuta et al. (2006) only reported a CAG repeat range of 40-57 for SBMA, with a mean of 46.6 ± 3.5 (5). Finally for this group, the two studies with the highest recorded minimum repeat number were reported in articles by Ni et al. (2015), who reported an average number of CAG repeats of 48.6 ± 3.5 (42-61), and an average age of weakness onset of 44.2 ± 10.2 (24-71) years (16), and Fu et al. (2013), who found a CAG repeat number range of between 42 and 53 (mean 47 ± 3). They proposed that a normal CAG repeat range is between 14 and 32, suggesting that anything over 40 repeats be regarded as abnormal (19).

One study, by Suzuki et al. (2007), did not fit into either group. This study subdivided patients with a CAG repeat size < 47 (short repeats) from those with ≥ 47 (long repeats) and then conducted electromyographic and nerve conduction studies on both groups separately (12). They reported a mean CAG repeat number of 47.8 ± 3.1 with a range of 41-57 repeats (12).

Discussion

CAG repeat number may account for approximately 60% of clinical heterogeneity in SBMA patients, with genetic, environmental and epigenetic factors also likely to play some role in influencing disease progression (1). However, the contribution of these relative unknowns aside, determining the correlation between the most commonly-mentioned SBMA symptom, weakness, and the primary clinical marker for the condition, CAG repeat number on the AR gene, might potentially uncover a strong indicator of disease onset that could be used to enable early detection, and therefore management, of SBMA. As such, this review is important and timely given that no other review to date has specifically investigated a possible connection between the age of onset of weakness in SBMA and CAG repeat length.

All of the studies investigated for this review addressed our first objective, with eleven of the thirteen indicating that a significant inverse correlation did exist between the CAG repeat number and onset of SBMA weakness (5,7,9–11,15–18) (Table 3). Although the study by Doyu et al. (1992) only just failed our initial screening due to poor population validity (56%), data collection validity (63%) and results validity (67%) (overall score 67%) (Table 4) we ultimately included it in this review despite the within-family comparisons which decreased its external validity (9). We felt that the use of disability scores to assess clinical severity in this paper, combined with the limited number of studies available, mitigated against its exclusion. However, notably, a single study did find that shorter CAG repeat number (<47) was associated with an older onset of weakness (12).

Only three out of the 13 studies included in this review failed to find a strong or even a moderate statistically significant correlation between CAG repeat number and age of onset of weakness, and these studies often had poor external validity (13,19). For example, the overall validity for the article by Tomik et al. (2006) was only 62%, primarily due to its poor population validity (33%; Table 4) (13). Specifically, the lack of age-matched healthy controls to compare EMG results against and the small sample size (11 SMBA patients and 3 carriers; see Table 3) significantly impacted the external validity of the study (13). However, the paper was included as it met the inclusion criteria for this review. Similarly, the study by Fu et al. (2013), also had a relatively low overall validity score of 71%, also mostly due to its poor external validity (50%) (Table 4). In this particular case, it was limited by the small population size and retrospective nature (indeed, the authors themselves apparently recognized this deficiency and suggested that any future characterization of the functional progression, and the clinical and electrophysiological aspects of SBMA, be conducted using larger scale prospective studies) (19). The study by Lee et al. (2005), which only found what the authors described as a “weak” association (r=0.4) between CAG repeat number and age of onset of weakness in SBMA (14), did pass screening validity with an overall validity score of 78%. However, it is notable that in this case, it too had low population validity (60%; Table 4) and a small sample size which, arguably, affect the conclusions that can be drawn from it. In this case too, the authors recommended that future prospective studies should involve a larger number of patients to better characterize the natural progression of the disease (14).

One final study, which reported only a moderate correlation between CAG repeat length and SBMA weakness (overall score 72%; Table 4), also failed screening due to its poor population and results validity (both 50%) (17). For example, this study had a poor results validity score due to its small sample size and lack of accountability for confounding factors (17). The authors recommended that a large-scale cohort study be conducted (17).

Specifically with regard to our second objective, the majority of studies examined here presented both CAG repeat number data and ages of onset of weakness such that these data could be compared across studies to determine the minimum and maximum number of repeats at age of weakness onset in SBMA (7,9,10,14,18). Rosenbohm et al. (2018) and Song et al. (2015) simply stated the CAG repeat ranges and the mean age-at-weakness-onset (11,17). Of the five studies that addressed the objective, CAG repeats ranged from the mid-thirties to the mid-fifties, which roughly coincides with the accepted marker of ≥ 38 repeats used to indicate the presence of SBMA (1), and all five studies also found that patients with larger repeat numbers had an earlier onset of weakness (7,9,10,14,18).

Conclusion

Weakness is the most commonly complained of symptom among SBMA patients (1). This review of the relevant SBMA literature has shown that the majority of studies investigating this facet of SBMA pathophysiology have demonstrated an inverse correlation between the number of CAG repeats and the age of weakness onset in SBMA patients. Furthermore, most of the aforementioned studies have proposed that the minimum number of CAG repeats associated with SBMA-linked weakness falls within at least the mid-to-late thirties range or greater. By exploring and revealing the relationship between this reliable marker of SBMA and a common clinical sign of the condition as we have done here, this review not only adds to the relatively scant literature on SBMA, but also, significantly, may facilitate earlier detection of the condition and its subsequent prompt treatment.

Declarations

Author’s Contributions

D.B. – Search, sorting and analysis of data. Author and editor of article. M.R. – Corresponding author, check of search and data analysis, and editor, of article.

Supporting Information

S1 File. Appendix A search terms.

S1 Fig. Appendix B EBL data.